Article Information
History
- August 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Sébastien Campagne1,2,*,
- Daniel Jutzi3,
- Florian Malard1,2,
- Maja Matoga1,
- Ksenija Romane1,
- Miki Feldmuller1,
- Martino Colombo4,5,
- Marc-David Ruepp3,* and
- Frédéric H-T. Allain1,*
- 1ETH Zurich, Department of Biology, Institute of Biochemistry, 8093 Zurich, Switzerland
- 2University of Bordeaux, Inserm U1212, CNRS UMR5320, ARNA Laboratory, 33077 Bordeaux, France
- 3United Kingdom Dementia Research Institute Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, London SE5 9NU, United Kingdom
- 4University of Bern, Department of Chemistry and Biochemistry, 3012 Bern, Switzerland
- 5Celgene Institute of Translational Research (CITRE), 41092 Seville, Spain
- ↵*Correspondence should be addressed to allain{at}bc.biol.ethz.ch, marc-david.ruepp{at}kcl.ac.uk or sebastien.campagne{at}inserm.fr
SC and DJ contributed equally to this work.
Posted August 30, 2022.
The cancer-associated RBM39 bridges the pre-mRNA, U1 and U2 snRNPs to regulate alternative splicing
